PURPOSE: Obstructive sleep apnea syndrome (OSAS) is characterized by repeated cycles of hypoxia occurring during sleep. This may cause the hypoxic oxidative stress (HOS). HOS may result in elevated levels of serum homocysteine in these patients. Few studies assessed serum levels of homocysteine among patients of OSA. Purpose was to assess serum homocysteine levels in OSA patients and to correlate them with the severity of disease.PSG.
METHODS: Study was conducted on 20 consecutive OSAS patients who underwent overnight. OSAS was ruled out by overnight PSG in 20 subjects and they were labeled as healthy control. There were 2 female and 18 male patients in both groups. The mean age of OSAS group patients was 46.5±8.78 year while it was 45.90±7.34 of healthy control. Severity of OSA was graded as mild, moderate and severe with apnea-hypopnea index (AHI) 5-10, 10-20 and >20 respectively revealed by PSG. Homocysteine levels in arterial blood of both patients and healthy participants were measured before and after overnight PSG. Statistical analysis was computed by applying chi square test.
RESULTS: The mean value of serum homocysteine was found to be 25.16 mmol/L in OSA patients while it was 10.28 mmol/L in control subjects. The difference was statistically significant (p <0.001). Serum homocysteine was 18.01 mmol/L, 22.06 mmol/l and 27.36 mmol/L among mild, moderate and severe OSA patients respectively; these values were higher than that of control subjects and were statistically significant.
CONCLUSION: Serum homocysteine levels were found to be increased in patients of OSA. Also elevated serum homocysteine levels were observed to be greater in more severe form of disease.
CLINICAL IMPLICATIONS: Increased level of serum homocysteine levels in OSA group was exhibited. Measurement of serum homocysteine is suggested be included in the diagnostic work up of OSA patients. The preventive treatment should be prescribed to patients suffering from OSA to evade the complications owing to high level of serum homocysteine.
DISCLOSURE: Harmanjit Hira, No Financial Disclosure Information; No Product/Research Disclosure Information